NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
OneSource Supports Second Generic Semaglutide Approval in Canada for Global Partners
OneSource Specialty Pharma's partner, Orbicular, has received Health Canada approval for a generic version of Ozempic (semaglutide injection). This marks the second generic semaglutide approval in Canada, which is the world's second-largest market for this drug. OneSource serves as the end-to-end manufacturing partner and will supply the product from its US FDA-approved flagship facility in Bengaluru. This milestone follows a recent tentative US approval and successful product launches in India earlier in March 2026.
முக்கிய அம்சங்கள்
Health Canada approval secured for generic semaglutide injection in the world's second-largest market.OneSource to provide end-to-end manufacturing from its US FDA-approved Bengaluru facility.Follows a recent tentative US approval, strengthening the company's global CDMO positioning.Company already supports multiple partners in India following product launches in March 2026.Leverages a workforce of 1,600+ professionals and 5 state-of-the-art manufacturing facilities.
👀 கவனிக்க வேண்டியவை
Investors should monitor the revenue ramp-up from the Canadian market as OneSource transitions to commercial supply. The company's success in the high-growth GLP-1 (semaglutide) space validates its technical expertise in complex drug-device combinations.
OneSource Partner Dr. Reddy's Receives Health Canada Approval for Generic Semaglutide Injection
OneSource Specialty Pharma's partner, Dr. Reddy's Laboratories, has received a Notice of Compliance from Health Canada for a generic version of Ozempic (Semaglutide Injection). OneSource serves as the exclusive CDMO partner for this program, providing scale-up and commercial manufacturing from its US-FDA approved flagship facility in Bengaluru. This approval validates OneSource's technical capabilities in the high-growth peptide and GLP-1 market segment. The company currently operates five state-of-the-art manufacturing facilities and employs a team of over 1,600 professionals.
முக்கிய அம்சங்கள்
Partner Dr. Reddy's receives Health Canada approval for Generic Semaglutide (Ozempic generic).OneSource to handle commercial manufacturing at its US-FDA approved flagship Bengaluru facility.The company operates 5 global regulatory-approved manufacturing facilities with 1,600+ professionals.Validation of OneSource's CDMO capabilities in complex peptide development and sterile injectables.
👀 கவனிக்க வேண்டியவை
Investors should view this as a major milestone that positions OneSource as a key player in the global GLP-1 supply chain. Monitor the stock for potential revenue growth as commercial production scales up for the Canadian market.
OneSource Specialty Pharma Receives EU GMP Certification for Bangalore Sterile Facility
OneSource Specialty Pharma's Bangalore-based Sterile Product Division (SPD) has successfully received the EU GMP Certificate of Compliance from the German regulatory authority. The certification, dated April 27, 2026, follows an inspection conducted on October 14, 2025, and confirms compliance with European standards for sterile products. This approval covers aseptically prepared small volume liquids, secondary packing, and quality control testing. This regulatory milestone significantly enhances the company's ability to serve the European market, complementing its existing approvals from the US-FDA, Health Canada, ANVISA, and TGA.
முக்கிய அம்சங்கள்
Received EU GMP Certificate from the German authority (Schleswig-Holstein) on April 27, 2026Certification covers aseptically prepared small volume liquids and quality control testingBangalore facility now holds approvals from 5 major global regulators including US-FDA and TGAThe Sterile Product Division maintains capabilities in liquid vials, lyophilised vials, and pre-filled syringes
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive step in the company's global expansion strategy as it opens up high-value European markets. Monitor for new contract manufacturing (CDMO) deal announcements following this certification.
OneSource Partner Secures Tentative US FDA Approval for Generic Ozempic (Semaglutide)
OneSource Specialty Pharma's partner, Orbicular, has received tentative US FDA approval for a generic version of Ozempic (Semaglutide Injection). OneSource serves as the CDMO partner, providing end-to-end manufacturing capabilities for the product from its US-FDA approved flagship site in Bangalore. This milestone validates OneSource's technical expertise in complex peptides and drug-device combinations. The company is now positioned for commercial supply readiness in the high-growth GLP-1 market.
முக்கிய அம்சங்கள்
Tentative US FDA approval received for generic Ozempic (Semaglutide Injection) by partner Orbicular.OneSource designated as the CDMO partner for manufacturing and global commercial supply.Production to be centralized at OneSource's US-FDA approved flagship facility in Bangalore.OneSource operates 5 state-of-the-art facilities with a workforce of over 1,600 professionals.
👀 கவனிக்க வேண்டியவை
Investors should monitor the timeline for final FDA approval and commercial launch, as this product addresses a multi-billion dollar global market. The development significantly enhances OneSource's profile as a high-end specialty CDMO.
OneSource Receives EU-GMP Certification Renewal for Flagship Unit II Facility
OneSource Specialty Pharma has successfully renewed its European Union Good Manufacturing Practices (EU-GMP) certification for its flagship Unit II facility in Bengaluru. This facility is a critical asset for the company, focusing on integrated biologics drug-substance and drug-product manufacturing. The renewal follows a successful inspection by a European regulatory authority, ensuring the company can continue supplying sterile injectables and drug-device combinations to the EU market. This certification validates the company's adherence to high-quality standards required for regulated international markets.
முக்கிய அம்சங்கள்
Successful renewal of EU-GMP certification for the flagship Unit II manufacturing facility in Bengaluru.Unit II provides integrated biologics drug-substance and drug-product manufacturing capabilities.The facility is equipped for specialized drug-device combinations and sterile injectable products.Certification ensures continued access and compliance for the European Union pharmaceutical market.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive regulatory milestone that secures the company's ability to serve the lucrative European market. The renewal reduces compliance risk and supports the company's growth in the specialty biologics and CDMO space.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
OneSource Specialty Pharma Achieves 'Leader' ESG Rating of 73 from NSE Sustainability
OneSource Specialty Pharma Limited has been assigned an Environmental, Social, and Governance (ESG) rating of 73 for FY25 by NSE Sustainability Ratings & Analytics Limited. This score places the company in the 'Leader' category, reflecting strong performance in sustainability and governance practices. Notably, the rating was assigned independently based on public domain information without the company's direct engagement. This high rating is likely to enhance the company's appeal to institutional investors and ESG-focused funds.
முக்கிய அம்சங்கள்
Assigned an ESG score of 73 for the financial year FY25Classified under the 'Leader' rating category by NSE Sustainability Ratings & AnalyticsRating was assigned independently based on public information without company solicitationDisclosure made in compliance with SEBI Master Circular dated January 30, 2026
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive validation of the company's governance and sustainability standards. While it doesn't impact immediate earnings, it may attract higher institutional interest from ESG-focused portfolios.
OneSource Specialty Pharma to Review Merger Scheme Before NCLT Filing
OneSource Specialty Pharma has received in-principle approval from BSE and NSE for its composite scheme of amalgamation involving Steriscience and Strides Pharma entities. During a board meeting on March 06, 2026, the directors decided to conduct a further internal review before proceeding with the formal NCLT filing. This review is scheduled to be completed within the six-month approval window granted by the stock exchanges. The proposed merger aims to integrate Steriscience's manufacturing facilities in Poland and Baroda into OneSource's operations.
முக்கிய அம்சங்கள்
In-principle approval received from stock exchanges for the merger of Steriscience and Strides Pharma units.Board of Directors decided on March 06, 2026, to undertake a further review before NCLT application.Review process to be finalized within the 6-month validity period of the exchange approvals.The scheme involves the acquisition of Steriscience facilities located in Poland and Baroda.The merger is being conducted under sections 230 to 232 of the Indian Companies Act and Singapore Companies Act.
👀 கவனிக்க வேண்டியவை
Investors should monitor the outcome of the internal review as any modifications to the scheme could affect the company's valuation. The stock remains a 'Watch' until the NCLT filing process officially commences.
OneSource Pharma Gets NSE/BSE No-Objection for Merger with Steriscience and Strides Entities
OneSource Specialty Pharma has cleared a major regulatory hurdle by receiving 'No-Objection' letters from NSE and BSE for its proposed multi-entity merger. The scheme involves the absorption of Steriscience Specialties, Brooks Steriscience, Steriscience Pte. (Singapore), and Strides Pharma Services into OneSource. This consolidation is aimed at creating a larger specialty pharma platform, though it remains subject to NCLT and shareholder approvals. Investors should carefully review the mandated disclosures regarding the impact on public shareholding and the integration of accumulated losses from the merging entities.
முக்கிய அம்சங்கள்
NSE and BSE issued 'No-Objection' letters on February 25, 2026, valid for a period of six months.The merger includes four transferor companies, including an international entity based in Singapore (Steriscience Pte. Limited).SEBI requires prominent disclosure of the pre and post-scheme shareholding patterns for promoters and public shareholders in the upcoming notice.The company must provide a detailed rationale for merging entities with accumulated losses and the resulting impact on OneSource's reserves.Final implementation remains subject to approvals from the NCLT Mumbai, Singapore Courts, and respective creditors.
👀 கவனிக்க வேண்டியவை
Investors should wait for the detailed explanatory statement to assess the share-swap ratio and the financial health of the entities being absorbed. This merger is a significant step for the company's growth but requires final NCLT clearance.
OneSource Secures SFDA Approval for Generic Ozempic in Saudi Arabia via Hikma Partnership
OneSource Specialty Pharma has received approval from the Saudi Food and Drug Authority (SFDA) to commercialize a generic version of Ozempic (semaglutide) in Saudi Arabia. The company has entered into an exclusive partnership with Hikma Pharmaceuticals, the largest pharma company in the MENA region, to handle commercialization and distribution. OneSource will manufacture the product at its integrated Biologics facility in Bengaluru, India. This approval marks a significant entry into one of the world's largest markets for GLP-1 therapies, positioning the company for high-growth revenue in the metabolic health segment.
முக்கிய அம்சங்கள்
Received SFDA approval for generic semaglutide (Ozempic®) in Saudi Arabia.Exclusive commercialization partnership with Hikma Pharmaceuticals for the MENA region.Manufacturing to be conducted at the company's state-of-the-art Bengaluru facility.Targeting Saudi Arabia, identified as one of the largest global markets for GLP-1 therapies.OneSource operates 5 global manufacturing facilities with a team of over 1,600 professionals.
👀 கவனிக்க வேண்டியவை
Investors should monitor the commercial rollout and subsequent revenue contribution from the MENA region, as this establishes OneSource as a key player in the high-value GLP-1 generic market. The stock may see positive momentum given the scale of the partnership with Hikma.
Promoter Group Acquires 4.43 Lakh Shares (0.39% Stake) of OneSource Specialty Pharma
Promoter group entities, Tenshi Pharmaceuticals Private Limited and Pronomz Ventures LLP, have increased their stake in OneSource Specialty Pharma by purchasing 443,906 shares from the open market. This acquisition represents approximately 0.39% of the company's total paid-up equity capital. The transactions were carried out between January 30, 2026, and February 04, 2026. Such insider buying is generally viewed as a sign of promoter confidence in the company's valuation and future growth prospects.
முக்கிய அம்சங்கள்
Promoter group acquired a total of 443,906 equity shares representing 0.39% of the company.Tenshi Pharmaceuticals Private Limited purchased 365,000 shares across three transactions.Pronomz Ventures LLP acquired 78,906 shares in two separate market transactions.The acquisition was conducted through the stock market between January 30 and February 04, 2026.Disclosures were made under SEBI Substantial Acquisition of Shares & Takeovers and Prohibition of Insider Trading regulations.
👀 கவனிக்க வேண்டியவை
Investors should take this as a positive signal of promoter commitment and confidence in the business. It may be worth monitoring the stock for further consolidation or accumulation by insiders at current levels.
OneSource Specialty Pharma reported a $10 million sequential revenue decline in Q3 FY26, primarily driven by deferred semaglutide approvals in the Canadian market and a strategic shift from MSAs to commercial supplies. Despite these near-term headwinds, management reiterated its FY28 guidance of $400 million in revenue and $160 million in EBITDA, excluding inorganic growth. The company is aggressively investing over INR 700 crores in capacity expansion and has doubled its flagship site workforce to prepare for a significant ramp-up expected in H2 FY27.
முக்கிய அம்சங்கள்
Q3 FY26 revenue and EBITDA declined by approximately $10 million sequentially due to deferred commercial launches.Reiterated long-term FY28 guidance of $400 million revenue and $160 million EBITDA.Aggressive capex of over INR 700 crores (~$100 million) is underway, with 75% of flagship site investment already committed.Currently holding INR 250 crores in customer advances for pre-booked manufacturing capacities.Flagship site workforce doubled year-to-date with the addition of 300 new full-time employees.
👀 கவனிக்க வேண்டியவை
Investors should focus on the H2 FY27 recovery timeline and regulatory approval milestones for semaglutide in Canada and emerging markets. While the next two quarters may remain soft, the reiterated FY28 guidance suggests significant long-term upside if execution remains on track.
Tenshi Pharmaceuticals Private Limited, a promoter entity of OneSource Specialty Pharma Limited, has acquired 200,000 equity shares from the open market. This transaction, completed on January 28, 2026, represents a 0.17% stake in the company's total equity capital. The acquisition was disclosed in compliance with SEBI's Substantial Acquisition of Shares and Insider Trading regulations. Promoter buying from the open market typically signals internal confidence in the company's long-term value and operational trajectory.
முக்கிய அம்சங்கள்
Tenshi Pharmaceuticals purchased 200,000 equity shares on January 28, 2026.The acquisition accounts for 0.17% of the company's total equity share capital.The transaction was executed via an open market purchase.The disclosure follows SEBI (SAST) and SEBI (PIT) regulatory requirements.
👀 கவனிக்க வேண்டியவை
This insider buying is a positive indicator of promoter conviction; investors may consider this a supportive factor for the stock price. Monitor for further accumulation by promoters as a sign of sustained confidence.
OneSource Specialty Pharma reported a weak Q3FY26 with revenues declining 26% YoY to ₹2,903 million and EBITDA falling 88% to ₹173 million due to delayed semaglutide approvals in Canada. The company issued a critical correction to its FY28 guidance, clarifying that revenue targets are $400-$500 million, not ₹400-₹500 million as previously stated. Despite a quarterly adjusted PAT loss of ₹472 million, management reaffirmed long-term targets of ~40% EBITDA margins and ROCE above 50%. The company noted that the order book remains strong and the biologics segment is seeing historic high interest.
முக்கிய அம்சங்கள்
Corrected FY28 revenue guidance to $400 million organic and $500 million total, a massive upward correction from the typo of ₹500 million.Q3FY26 revenue dropped 26% YoY to ₹2,903 million, impacted by transition delays from MSA to CSA phases in Canada.EBITDA margins collapsed to 6% from 36% YoY, leading to an adjusted PAT loss of ₹472 million.Effective interest rate (EIR) improved by 200bps YoY to below 9%, showing better debt management.Reaffirmed FY28 outlook of ~40% EBITDA margin and Net-to-EBITDA ratio below 1.5x.
👀 கவனிக்க வேண்டியவை
Investors should focus on the timeline for Canadian regulatory approvals for semaglutide, which is the primary bottleneck for current revenue. While the corrected USD-denominated FY28 guidance is highly positive, the current operational volatility suggests waiting for a recovery in EBITDA margins before increasing exposure.
OneSource Q3FY26 Revenue Drops 26% to ₹2,903M; EBITDA Margin Shrinks to 6%
OneSource Specialty Pharma reported a weak Q3FY26 with revenue declining 26% YoY to ₹2,903 million, primarily due to delayed customer approvals for semaglutide in Canada. EBITDA crashed 88% YoY to ₹173 million as margins compressed significantly from 36% to 6% due to a fixed cost base and lower operating leverage. Despite the quarterly setback, the company reaffirmed its ambitious FY28 guidance of $400-$500 million in revenue with ~40% EBITDA margins. The biologics segment remains a bright spot with a 4x growth in the project funnel and the onboarding of a major US biosimilar player.
முக்கிய அம்சங்கள்
Revenue declined 26% YoY to ₹2,903 million due to transitional delays in the Canadian market for semaglutide.EBITDA plummeted 88% YoY to ₹173 million, with margins shrinking by 3,018 bps to 6%.Reported an Adjusted PAT loss of ₹472 million compared to a profit of ₹672 million in Q3FY25.Reaffirmed FY28 organic revenue guidance of $400 million and steady-state EBITDA margin outlook of ~40%.Biologics funnel grew 4x compared to FY25, with 20 new MSAs and licensing deals signed during the year.
👀 கவனிக்க வேண்டியவை
Investors should treat this as a transitional quarter and closely monitor the timeline for Canadian regulatory approvals for semaglutide. While current earnings are weak, the long-term investment thesis depends on the company's ability to execute its high-margin FY28 guidance and scale its biologics CDMO business.
OneSource Specialty Pharma Q3 Revenue Drops 22% QoQ; Reports ₹621.8 Million Net Loss
OneSource Specialty Pharma (formerly Stelis Biopharma) reported a weak Q3 FY26 with standalone revenue falling 22.6% sequentially to ₹2,902.2 million. The company posted a net loss of ₹621.8 million, a sharp reversal from the ₹371 million profit in Q2 FY26, driven by increased 'other expenses' and exceptional costs. Exceptional items totaling ₹70.9 million were linked to merger integration and employee settlements. While 9M FY26 performance shows revenue growth of 20% YoY, the quarterly volatility remains a concern for short-term performance.
முக்கிய அம்சங்கள்
Standalone Revenue from operations declined to ₹2,902.2 million in Q3 FY26 from ₹3,751.9 million in Q2 FY26.Reported a Net Loss of ₹621.85 million for the quarter, compared to a profit of ₹371.01 million in the preceding quarter.Exceptional items of ₹70.9 million included ₹41.47 million for one-time employee settlements and merger-related expenses.9M FY26 revenue improved to ₹9,864.2 million from ₹8,221.8 million in the corresponding period last year.Ongoing Composite Scheme of Arrangement involves amalgamation with multiple entities including Brooks Steriscience and Steriscience Pte.
👀 கவனிக்க வேண்டியவை
Investors should monitor the progress of the Composite Scheme of Arrangement and the company's ability to stabilize margins post-merger. The current operational loss and revenue contraction suggest a cautious approach is warranted until post-merger synergies are realized.
OneSource Specialty Pharma Merges Singapore Subsidiaries with $41.95M Combined Turnover
OneSource Specialty Pharma has completed the amalgamation of its two Singapore-based wholly owned subsidiaries, Stelis Pte. Limited and OneSource Specialty Pte. Limited, effective January 1, 2026. Stelis reported a turnover of USD 7.86 million for FY25, while OneSource Specialty Pte. recorded USD 34.09 million. The merger is designed to simplify the corporate hierarchy and reduce redundant administrative, legal, and compliance costs. Since both are 100% owned subsidiaries, the transaction has no impact on the consolidated financial position or the shareholding pattern of the parent company.
முக்கிய அம்சங்கள்
Amalgamation of Stelis Pte. Limited into OneSource Specialty Pte. Limited effective January 1, 2026.Stelis Pte. Limited reported a turnover of USD 7.86 million for the financial year ended March 31, 2025.OneSource Specialty Pte. Limited reported a turnover of USD 34.09 million for the financial year ended March 31, 2025.Restructuring aims to enhance operational efficiency and eliminate redundant administrative and compliance costs.The transaction is between wholly owned subsidiaries and does not affect the consolidated financials or shareholding pattern.
👀 கவனிக்க வேண்டியவை
This is a routine internal restructuring aimed at cost optimization and operational efficiency. Investors need not take any immediate action as the consolidated fundamentals of the company remain unchanged.
OneSource Specialty Pharma Limited (formerly Stelis Biopharma) has announced that India Ratings & Research (Ind-Ra) has affirmed its credit rating for additional bank loan facilities. The rating is maintained at [IND A-/Positive], which is consistent with the previous rating issued on June 03, 2025. This affirmation reflects the agency's view on the company's creditworthiness and financial stability. The 'Positive' outlook indicates potential for a future rating upgrade based on sustained operational performance.
முக்கிய அம்சங்கள்
India Ratings & Research (Ind-Ra) affirmed the credit rating at [IND A-/Positive].The rating applies to the company's additional bank loan facilities.The current rating remains consistent with the previous assessment from June 03, 2025.The 'Positive' outlook suggests a favorable credit trajectory for the specialty pharma firm.
👀 கவனிக்க வேண்டியவை
Investors should take confidence in the 'Positive' outlook, which suggests the company is maintaining its financial health. Monitor the company's ability to convert this outlook into a formal rating upgrade through improved cash flows and debt management.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
